Literature DB >> 7067726

Pharmacokinetics of viloxazine hydrochloride in man.

B Vandel, S Vandel, J M Jounet, D Blum.   

Abstract

The pharmacokinetic characteristics of a new antidepressant, viloxazine hydrochloride, were investigated in five males and five females to study sex differences. Plasma levels were determined over a period of 9 h after a single dose of viloxazine of 100 mg (expressed as base). The half life of the drug was in the range of 2.19 - 4.21 for females and 2.61 - 4.31 h for males. The maximum plasma levels occurred in 29 - 171 min of the oral dose for females and 54 - 155 min for males. They reached 1382 - 1769 ng/ml-l for females and 1108 - 2932 ng/ml for males. Pharmacokinetic data were not statistically different between males and females.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7067726     DOI： 10.1007/BF03189545

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


  7 in total

1.  Some preliminary observations on ICI 58 834, a new psychotropic agent, in man.

Authors:  M Kirby; P Turner
Journal:  Br J Clin Pharmacol       Date:  1974-04       Impact factor: 4.335

2.  Gas-liquid chromatographic estimation in blood of ICI 58 834.

Authors:  D E Case
Journal:  J Pharm Pharmacol       Date:  1973-10       Impact factor: 3.765

3.  Blood level studies with viloxazine hydrochloride in man.

Authors:  P F Bayliss; D E Case
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

4.  The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans.

Authors:  D E Case; P R Reeves
Journal:  Xenobiotica       Date:  1975-02       Impact factor: 1.908

5.  Influence of neuroticism on oral absorption of diazepam.

Authors:  S Nakano; N Ogawa; Y Kawazu
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

6.  Clinical profile and serum concentration of viloxazine as compared to amitriptyline.

Authors:  B Müller-Oerlinghausen; E Rüther
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1979-07

7.  Clinical pharmacology of viloxazine hydrochloride.

Authors:  B Vandel; S Vandel; G Allers; R Volmat
Journal:  Pharmacopsychiatria       Date:  1981-03
  7 in total
  5 in total

1.  Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

Authors:  F Pisani; A Fazio; E Spina; C Artesi; B Pisani; M Russo; R Trio; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.

Authors:  Christopher L Robinson; Katelyn Parker; Saurabh Kataria; Evan Downs; Rajesh Supra; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Health Psychol Res       Date:  2022-09-23

Review 3.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

4.  Sex-dependent modulation of treatment response.

Authors:  David R Rubinow; Molly Moore
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

5.  Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.

Authors:  Azmi Nasser; Roberto Gomeni; Zhao Wang; Alisa R Kosheleff; Lanyi Xie; Lilian W Adeojo; Stefan Schwabe
Journal:  J Clin Pharmacol       Date:  2021-08-08       Impact factor: 2.860
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.